Brokerages Set Kura Oncology, Inc. (NASDAQ:KURA) Price Target at $25.62

Kura Oncology, Inc. (NASDAQ:KURA) has earned a consensus recommendation of “Moderate Buy” from the thirteen brokerages that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $25.40.

Several analysts recently commented on KURA shares. Morgan Stanley set a $24.00 price target on Kura Oncology in a research report on Monday. Jefferies Financial Group set a $24.00 price objective on Kura Oncology in a report on Thursday, May 28th. CLSA set a $24.00 target price on shares of Kura Oncology in a research note on Thursday, June 4th. Citizens Jmp reaffirmed a “market outperform” rating and set a $24.00 target price on shares of Kura Oncology in a research note on Monday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a report on Thursday, June 4th.

Kura Oncology Trading Up 4.3%

KURA stock opened at $12.40 on Friday. Kura Oncology has a 12-month low of $7.36 and a 12-month high of $12.90. The business’s 50-day moving average is $10.59 and its 200 day moving average is $9.50. The company has a current ratio of 4.73, a quick ratio of 4.71 and a debt-to-equity ratio of 0.12. The stock has a market cap of $1.10 billion, a price-to-earnings ratio of -3.68 and a beta of 0.38.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Wednesday, August 12th. The company reported ($0.77) EPS for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.11. The business had revenue of $20.87 million during the quarter, compared to analysts’ expectations of $20.16 million. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%. On average, sell-side analysts anticipate that Kura Oncology will post -3.23 EPS for the current fiscal year.

Insider Buying and Selling at Kura Oncology

In related news, insider Teresa Brophy Bair sold 31,487 shares of the business’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $12.63, for a total transaction of $397,680.81. Following the transaction, the insider directly owned 195,444 shares in the company, valued at approximately $2,468,457.72. The trade was a 13.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Mollie Leoni sold 84,929 shares of the business’s stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $9.82, for a total transaction of $834,002.78. Following the transaction, the insider owned 182,345 shares in the company, valued at $1,790,627.90. The trade was a 31.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 120,761 shares of company stock valued at $1,283,346. Corporate insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in shares of Kura Oncology in the second quarter valued at approximately $115,286,000. Suvretta Capital Management LLC lifted its position in Kura Oncology by 5.7% during the fourth quarter. Suvretta Capital Management LLC now owns 8,575,422 shares of the company’s stock worth $89,099,000 after buying an additional 459,422 shares in the last quarter. Vanguard Group Inc. lifted its position in Kura Oncology by 0.7% during the fourth quarter. Vanguard Group Inc. now owns 5,507,627 shares of the company’s stock worth $57,224,000 after buying an additional 39,105 shares in the last quarter. Armistice Capital LLC boosted its stake in Kura Oncology by 5.7% during the fourth quarter. Armistice Capital LLC now owns 4,936,000 shares of the company’s stock worth $51,285,000 after buying an additional 264,000 shares during the last quarter. Finally, State Street Corp boosted its stake in Kura Oncology by 47.5% during the fourth quarter. State Street Corp now owns 4,931,090 shares of the company’s stock worth $51,234,000 after buying an additional 1,587,959 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.